Skip to main content
SpringerLink
Log in

Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) in advanced gastric cancer

  • Short Communication
  • Gastric Cancer, FAP Combination
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Twenty patients (15 male, 5 female) with nonresectable gastric adenocarcinoma were treated with FAP (5-fluorouracil 300 mg/m2 IV on days 1–5, adriamycin 50 mg/m2 IV on day 1, cisplatin 20 mg/m2 IV on day 1–5). Each course was repeated every 21 days. Eighteen patients were evaluable for response. The median age was 51 years, the range extending from 34 to 68. None had undergone chemotherapy. The median Karnofsky performance score was 80%. Nine (50%) partial responses (PR) and eight (44%) cases of stable disease (SD) were observed. One patients showed progression of the disease and died after 6 months. The median duration of response was 6+ months for PR and 6 months for SD. The median survival was 12 months. FAP toxicity was moderate, with the median WBC nadir 3.2×109/l (range 0.7–4.2). One patient in PR died of septicemia. Nausea and vomiting were not dose-limiting. Neuropathy was mild in four and moderate in two patients. This FAP combination appears to be as effective with respect to response rate and duration as reported for 5-fluorouracil, adriamycin and mitomycin C (FAM).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bitran JD, Desser RK, Kozloff MF, Billings AA, Shapiro CM (1979) Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluororouracil, adriamycin, and mitomycin C (FAM). Cancer Treat Rep 63: 2049

    Google Scholar 

  2. Gastrointestinal Tumor Study Group (1981) A comparative clinical assessment of combination chemotherapy in the management of advanced gastric carcinoma. Cancer 49: 1362

    Google Scholar 

  3. Leichman L, McDonald B, Dindogru A, Samson M, Vaitkevicius VK (1984) Cisplatin, an active drug in the treatment of disseminated gastric cancer. Cancer 53: 18

    Google Scholar 

  4. Levi JA, Dalley DN, Aroney RS (1979) Improved combination chemotherapy in advanced gastric cancer. Br Med J II: 1471

    Google Scholar 

  5. MacDonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, Smith F, Boiron M, Gisselbrecht C, Brunet R, Lagarde C (1980) 5-Fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93: 533

    Google Scholar 

  6. Moertel CG (1975) Clinical management of advanced gastrointestinal cancer. Cancer 36: 675

    Google Scholar 

  7. Moertel CG, Lavin PT (1979) Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63: 1863

    Google Scholar 

  8. Moertel CG, Mittelman JA, Bakemeier RF, Engstrom P, Hanley J (1976) Sequential and combination chemotherapy of advanced gastric cancer. Cancer 38: 678

    Google Scholar 

  9. Pannetierre F, Heilbrun L (1979) Comparison of two different combinations of adriamycin, mitomycin C and 5-fluorouracil in the management of gastric carcinoma. Proc Am Soc Clin Oncol 20: 315

    Google Scholar 

  10. Woolley P, Smith F, Estevez R, Gisselbrecht C, Alvarez C, Boiron M, Machado C, Lagarde C and Schein P (1981). A phase II trial of 5-FU, adriamycin and cisplatin (FAP) in advanced gastric cancer. Proc Am Soc Clin Oncol 481:455

    Google Scholar 

  11. World Health Organization (1979) Handbook for reporting results of cancer treatment. WHO, Geneva, p. 16 (Offset publication no. 48)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, University Hospital St. Radboud, Nijmegen

    S. H. Yap

  2. Department of General Surgery, University Hospital St. Radboud, Nijmegen

    T. Wobbes

  3. Groot Ziekengasthuis, 's-Hertogenbosch

    J. T. M. Burghouts

  4. St. Jozef Ziekenhuis, Eindhoven

    F. E. van Dam

  5. Catharina Ziekenhuis, Eindhoven

    H. F. P. Hillen

  6. St. Geertruiden Ziekenhuis, Deventer

    G. J. Hoogendoorn

  7. Ziekenhuis Venlo-Tegelen, Venlo

    H. Scheerder

  8. Ziekenhuis Oudenrijn, Utrecht

    S. G. L. van der Vegt

  9. Department of Internal Medicine, Division of Medical Oncology, University Hospital St. Radboud, Bostbox 9101, 6500 HB, Nijmegen, The Netherlands

    D. J. Th. Wagener

Authors
  1. D. J. Th. Wagener
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. H. Yap
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Wobbes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. T. M. Burghouts
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. E. van Dam
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. F. P. Hillen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. J. Hoogendoorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. Scheerder
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. G. L. van der Vegt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wagener, D.J.T., Yap, S.H., Wobbes, T. et al. Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) in advanced gastric cancer. Cancer Chemother. Pharmacol. 15, 86–87 (1985). https://doi.org/10.1007/BF00257302

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00257302

Keywords

Search

Navigation